Iambic Therapeutics Targets $155 Million in AI-Driven IPO

At the $16 midpoint of its pricing range, the company expects to secure approximately $135 million in net proceeds, a figure that climbs if underwriters utilize their option to purchase an additional 1.4 million shares. These resources, combined with current capital, are earmarked to cover operating expenses and infrastructure requirements for the next four years.

Following the offering and a private placement, Iambic anticipates having roughly 48.8 million shares outstanding. This valuation suggests a market capitalization exceeding $780 million at the midpoint price. The company has formally applied to list its stock on the Nasdaq Global Select Market under the ticker symbol IAM.